Why BGPT?
logo

Graphs Built From Reported Results

Plot exact reported values with provenance, so every point traces back to a paper.Know what the science actually supports before you trust the answer.

Press Enter ↡ to create graph



    Explore by Goal












     Quick Analysis Plan


    The requested plot cannot be built as specified: the supplied evidence records contain Boditech iCHROMA IgG cutoff-index data only (NIBSC external quality controls; infection/convalescence/vaccination kinetics) and no SARS-CoV-2 neutralization titers (e.g., VNT, PRNT, IC50) to plot against (). Plotted below are the available iCHROMA datasets; pairing with neutralization requires uploading a dataset containing neutralizing antibody titers.


     Long Analysis Plan


    Evidence check: no neutralization data exist in the supplied records

    The two supplied claim-level records describe the Boditech iCHROMA Covid-19 IgG fluorescence immunoassay (FIA) reporting a cutoff index (negative <0.9, indeterminate 0.9–1.1, positive >1.1) using a sandwich immunodetection read on the iCHROMA II device (). Neither record reports plaque-reduction neutralization tests (PRNT), microneutralization, pseudovirus IC50, or any live-virus neutralizing titer. A binding-IgG index and a neutralization titer measure distinct immunological quantities and cannot be legitimately plotted against each other without a co-measured dataset. The correct ARRANGE plan therefore: (1) visualize the iCHROMA data that exist, and (2) flag the missing neutralization axis.

    What can be plotted: iCHROMA IgG index datasets

    Dataset A β€” NIBSC external quality control, 33 positive controls (index 19.5–29.0; mean 23.75 Β± 2.53) and 33 negative controls (all 0.00), run July 7–August 20, 2020 ():

    Dataset B β€” antibody kinetics: one infected subject (index 5.2 at day 11; 39.1 at day 20; days 20–100 range 26.8–46.7, mean 36.5), 30 convalescent subjects (days 40–90, range 14.0–32.6, mean 20.65, all positive), and 12 vaccinees split by prior infection status ():

    Critical limitations and what is missing

    These are small, single-platform studies with a declared manufacturer consultancy conflict of interest in the kinetics study; the QC study used pooled reference materials rather than patient samples, with no lot-to-lot or cross-device testing. Binding IgG positivity does not establish neutralizing capacity; correlating iCHROMA index with a neutralization titer would require a cohort where both assays were run on the same specimens β€” data not present here. Any inferred iCHROMA-to-neutralization correlation from these records would be a hypothesis, not a plotted observation.



    Feedback:    

    Updated: October 28, 2026

     Analysis Wizard



    Loading and arranging iCHROMA IgG index datasets from the NIBSC QC and kinetics records to build organized, publication-ready Plotly visualizations while flagging the absent neutralization titers.



     Hypothesis Graveyard


    Assuming the NIBSC QC index range (19.5–29.0) reflects typical patient titers β€” falsified by the kinetics study, where patient indices span 0–46.7, indicating QC materials sit in a narrow high-titer band unrepresentative of clinical heterogeneity.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending